C3 glomerulopathy

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
4 Unique sponsors
8 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
J Anti-infectives (ATC J) 1
L Oncology (ATC L) 2
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Vaccine 3 substances
Complement inhibitor (C3) 1 substance
ACE inhibitor 1 substance
Phase III: 3 Phase II: 1 Phase III/IV: 1 Phase I: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • Apellis Pharmaceuticals Inc. Commercial
    N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (DE-O-ACETYLATED) CONJUGATED TO TETANUS TOXOID, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN; PEGCETACOPLAN; PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2023-504625-39-00 8 countries 2023 n=66 Orphan
    Ended
  • Apellis Pharmaceuticals Inc. Commercial
    PEGCETACOPLAN
    2024-514130-20-00 4 countries 2022 n=19 Orphan
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN; IPTACOPAN HYDROCHLORIDE
    2023-509331-83-00 7 countries 2021 n=37 Orphan
    Recruiting

Phase II

1 trial
  • Region Skane Academic
    ALISKIREN; ENALAPRIL MALEATE
    2024-515892-36-00 1 country 2020 n=30
    Ended

Phase III/IV

1 trial
  • Novartis Pharma AG Commercial
    IPTACOPAN; IPTACOPAN HYDROCHLORIDE
    2023-509343-27-00 7 countries 2019 n=50 Orphan
    Recruiting

Phase I

1 trial
  • Eleva GmbH Commercial
    IMP not specified
    2024-517992-19-00 11 countries 2025 n=58
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase III/IV, Phase III 2
Apellis Pharmaceuticals Inc. Commercial 2 Phase III 0
Eleva GmbH Commercial 1 Phase I 1
Region Skane Academic 1 Phase II 0
New trials by year
2019
1
2020
1
2021
1
2022
1
2023
1
2025
1
← All indication landscapes